FRE2 Antibody

What is FRS2 and why is it significant in cell signaling research?

FRS2 (also known as SNT and FRS2-alpha) is a 70-90 kDa member of the FRS family of lipid-anchored docking proteins. It serves as a critical intermediary between FGF and TRK receptors and their Ras/MAPK signaling cascades . Human FRS2 is 512 amino acids in length and contains three key structural elements: a membrane-anchoring myristoylation signal (amino acids 1-6), a PTB domain that interacts with FGF and NGF receptors (amino acids 13-115), and a C-terminal tyrosine-rich region that functions as a docking site for Grb2 and Shp2 (amino acids 196-471) .

The significance of FRS2 lies in its role as an adapter protein that translates receptor activation into downstream signaling events. When studying receptor tyrosine kinase signaling, FRS2 antibodies allow researchers to monitor this critical junction in cellular communication pathways, making them invaluable for investigating developmental processes, cancer biology, and neurological signaling.

What specific applications are FRS2 antibodies validated for?

FRS2 antibodies have been validated for multiple research applications, with performance characteristics varying based on antibody clone and format. Based on available research data, FRS2 antibodies can be reliably used for:

• Western blot analysis of cell lysates

• Immunohistochemistry (IHC) on paraffin-embedded tissue sections

• Immunoprecipitation studies

• Immunofluorescence microscopy

• Flow cytometry (with appropriate antibody format)

Notable experimental evidence demonstrates successful detection of FRS2 in liver cancer tissue using sheep anti-human FRS2 antigen affinity-purified polyclonal antibody at 1 μg/mL, with specific staining localized to cancer cell cytoplasm and cell membranes .

How should FRS2 antibodies be stored and handled to maintain optimal activity?

Proper storage and handling are crucial for maintaining antibody performance. For FRS2 antibodies, follow these evidence-based practices:

• Use a manual defrost freezer and avoid repeated freeze-thaw cycles which can denature antibody proteins

• Store unopened antibody at -20°C to -70°C for up to 12 months from the date of receipt

• After reconstitution, store at 2-8°C under sterile conditions for up to 1 month

• For long-term storage after reconstitution, aliquot and store at -20°C to -70°C for up to 6 months under sterile conditions

• When handling, minimize exposure to light if the antibody is conjugated to a fluorophore

• Avoid contamination by using sterile technique when preparing working dilutions

Properly stored and handled antibodies will maintain their binding specificity and signal intensity across experiments, ensuring reproducible results.

What are the optimal conditions for detecting FRS2 in different cellular compartments?

FRS2 localization varies depending on cellular activation state, with distribution between membrane, cytoplasmic, and potentially nuclear compartments. For optimal detection in different cellular compartments:

When studying FRS2 in liver cancer tissue, researchers have successfully used overnight incubation at 4°C with antibody concentration of 1 μg/mL followed by HRP-DAB detection systems . The specific staining pattern observed was primarily localized to cancer cell cytoplasm and cell membranes, suggesting careful optimization is needed when investigating different cellular compartments.

How can FRS2 antibodies be validated for specificity in experimental systems?

Validating antibody specificity is crucial for reliable research outcomes. For FRS2 antibodies, implement these validation approaches:

• Western blot analysis - Verify a single band of appropriate molecular weight (70-90 kDa for FRS2)

• Knockout/knockdown controls - Compare staining in FRS2-expressing vs. FRS2-depleted samples

• Peptide competition assay - Pre-incubate antibody with immunizing peptide (e.g., recombinant human FRS2 Asn121-Asn449) to block specific binding

• Multi-antibody validation - Compare staining patterns using antibodies targeting different FRS2 epitopes

• Phosphorylation-specific validation - For phospho-FRS2 antibodies, treat samples with phosphatases

Importantly, when selecting validation methods, consider the experimental context. For instance, in studies examining FRS2 involvement in FGFR-mediated signaling, validation should include controls with and without appropriate growth factor stimulation to confirm detection of physiologically relevant changes.

What methodological approaches help distinguish FRS2 (FRS2-alpha) from FRS3 (FRS2-beta)?

FRS2 and FRS3 share structural and functional similarities, making specific detection challenging. Implement these approaches to ensure FRS2-specific detection:

• Epitope selection - Choose antibodies targeting regions with lowest sequence homology between FRS2 and FRS3

• Recombinant protein controls - Run parallel assays with purified FRS2 and FRS3 to evaluate cross-reactivity

• Expression pattern analysis - Leverage known differential expression patterns in specific tissues

• Size discrimination - FRS2 typically appears at 70-90 kDa while FRS3 has a slightly different molecular weight

• Immunodepletion approach - Sequential immunoprecipitation with FRS3-specific antibodies followed by FRS2 detection

Researchers should note that human FRS2 shares 99% and 94% amino acid identity with canine and mouse FRS2 respectively (in the region spanning amino acids 121-449) , which has implications for cross-species studies, but maintains sufficient difference from FRS3 to enable selective detection with properly validated antibodies.

How can FRS2 antibodies be effectively used in multiplex immunostaining protocols?

Multiplex detection involving FRS2 requires careful planning to avoid antibody cross-reactivity and signal interference. Follow these evidence-based approaches:

• Sequential staining protocol - For multiple primary antibodies from the same species:

  • Apply first primary antibody at lower concentration

  • Detect with first secondary antibody

  • Block available binding sites on first primary antibody

  • Apply second primary antibody

  • Detect with spectrally distinct second secondary antibody

• Antibody format selection - Consider using F(ab) or F(ab')2 fragment antibodies when staining tissues with high Fc receptor expression (like lymph nodes or spleen) to reduce non-specific binding

• Panel design considerations:

  • When examining FRS2 alongside its signaling partners (e.g., FGFRs, Grb2, Shp2), ensure primary antibodies are raised in different species

  • For phosphorylation-specific multiplex studies, reserve one channel for total FRS2 and another for phospho-FRS2

  • Include nuclear counterstain compatible with your fluorophore selection

For optimal results in IHC applications, researchers have successfully used sheep anti-human FRS2 antibody at 1 μg/mL with HRP-DAB detection systems, which can be combined with other detection methods in multiplex protocols .

What are the methodological considerations for quantitative analysis of FRS2 in signaling pathways?

Quantitative analysis of FRS2 in signaling pathways requires rigorous technical approaches:

• Standardized stimulation protocols - For FGF or NGF receptor activation, use defined concentrations and exposure times

• Temporal analysis design - Collect samples at multiple timepoints post-stimulation (0, 5, 15, 30, 60 min) to capture phosphorylation dynamics

• Phosphorylation site-specific detection - Use antibodies targeting specific phosphorylated residues within the C-terminal tyrosine-rich region (aa 196-471)

• Signal normalization strategy:

  • Normalize phospho-FRS2 signal to total FRS2

  • Include loading controls (GAPDH, β-actin) for Western blot applications

  • For immunofluorescence, normalize to cell number or area

• Quantitative considerations for different applications:

Researchers should be aware that FRS2 exists in multiple phosphorylation states that affect antibody recognition, particularly when using phospho-specific antibodies. Calibration curves with recombinant phosphorylated standards are recommended for absolute quantification.

What strategies can overcome common challenges in FRS2 detection in different experimental systems?

Researchers frequently encounter specific challenges when working with FRS2 antibodies. Here are evidence-based solutions:

• High background in IHC/ICC applications:

  • Use F(ab) or F(ab')2 fragment antibodies to prevent Fc receptor binding in tissues with high Fc receptor expression

  • Increase blocking time and concentration (5% BSA or 10% serum from secondary antibody host species)

  • Reduce primary antibody concentration while extending incubation time

• Weak signal in Western blot:

  • Enrich target protein through immunoprecipitation before Western blot

  • Use enhanced chemiluminescence (ECL) substrates with higher sensitivity

  • Increase protein loading while ensuring lanes run evenly

  • For phospho-FRS2 detection, add phosphatase inhibitors to all buffers

• Inconsistent results across tissue types:

  • Optimize fixation protocol for each tissue type

  • For liver cancer tissue, overnight incubation at 4°C with 1 μg/mL antibody concentration has shown specific cytoplasmic and membrane staining

• Cross-reactivity issues:

  • Pre-absorb antibody with recombinant proteins of potential cross-reactive targets

  • Validate with knockout/knockdown controls

  • Consider computational techniques like alchemical free energy perturbation (FEP) to predict antibody specificity before experimental application

How can advanced computational methods aid in FRS2 antibody selection and application?

Recent advances in computational biology offer powerful tools for antibody research:

• Epitope prediction and antibody design:

  • Alchemical free energy perturbation (FEP) can predict the effects of mutations on both binding affinity and structural stability of antibodies

  • These calculations can be automated for large-scale evaluation of antibody variants

  • Statistical uncertainty estimates help researchers select the most promising antibody candidates

• Binding mode identification:

  • Computational models can identify different binding modes associated with particular ligands

  • This allows discrimination between highly similar epitopes that cannot be experimentally dissociated

  • Such approaches enable the design of antibodies with customized specificity profiles

• Application to FRS2 research:

  • Computational methods can predict which antibodies will best distinguish between phosphorylated and non-phosphorylated forms of FRS2

  • They can identify antibodies likely to cross-react with other FRS family members

  • Models can suggest optimal antibody pairs for sandwich immunoassays

For researchers interested in utilizing computational methods, it's important to note that while these approaches significantly enhance antibody selection, experimental validation remains essential, particularly for detecting subtle differences in FRS2 conformational states.

What novel applications are emerging for FRS2 antibodies in disease research?

FRS2 antibodies are finding new applications in disease-focused research:

• Cancer biomarker development:

  • FRS2 has been detected in liver cancer tissue using immunohistochemistry, showing specific staining in cancer cell cytoplasm and membranes

  • Antibodies targeting specific phosphorylation sites on FRS2 may serve as indicators of pathway activation in cancers dependent on FGF signaling

• Therapeutic antibody development:

  • Antibodies that modulate FRS2-mediated signaling could potentially disrupt oncogenic signaling pathways

  • Recent techniques like cell-free expression and screening platforms can accelerate the discovery and characterization of such antibodies

• Combination with emerging technologies:

  • Integration with synthetic biology approaches, such as engineered FRS2 variants with modified docking sites

  • Application in proximity labeling methods (BioID, APEX) to map FRS2 interactome under different conditions

  • Use in spatial transcriptomics/proteomics to correlate FRS2 activation with spatial gene expression patterns

• Translational research applications:

  • Development of immunotargeting vaccines that leverage antibody-mediated delivery of antigens to antigen-presenting cells

  • These approaches could be adapted to target FRS2-expressing cells in certain pathological conditions

What are the current limitations in FRS2 antibody technology and anticipated developments?

Current limitations in FRS2 antibody research include:

• Limited epitope coverage - Most commercially available antibodies target a restricted set of epitopes

• Variable batch-to-batch reproducibility in polyclonal preparations

• Incomplete validation across all potential applications and tissue types

• Challenges in detecting specific phosphorylation patterns relevant to different signaling outcomes

Anticipated future developments include:

• Recombinant antibody technology producing highly consistent FRS2 antibodies with defined specificity

• Novel antibody formats with enhanced tissue penetration and reduced background

• Multiplexed detection systems allowing simultaneous visualization of FRS2 with multiple binding partners

• Integration with single-cell technologies to reveal cell-specific signaling patterns

• Computational antibody design tailoring specificity for particular FRS2 conformational states

As research continues, we can expect the development of more sophisticated tools that will enable increasingly detailed analysis of FRS2's role in normal physiology and disease states, particularly in cancer and developmental disorders where FGF signaling plays a crucial role.